Fundraising FoxLUCA Science
7 known investors
Find your way into LUCA Science
Sign up to see every warm intro you have to LUCA Science
- Paths you didn't know you had: your email and LinkedIn already hold routes to the LUCA Science team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
LUCA Science develops mitochondrial therapies that supply functional, storable mitochondria to damaged or dysfunctional cells and tissues to restore cellular energy production, targeting conditions such as ischemia-reperfusion injuries including cerebral and myocardial infarction. The company works in the biopharmaceutical field, building a platform based on its proprietary iMIT mitochondria technology.
Investors · 7
How we know: Asahi Kasei Corporate Venture Capital's portfolio page · Not right? Tell us
How we know: Fast Track Initiative's portfolio page · funding news · privateequitywire.co.uk · Not right? Tell us
How we know: Remiges Ventures, Inc.'s portfolio page · a partner's Signal profile · Not right? Tell us
How we know: funding news · 4biocapital.com · Not right? Tell us
How we know: a partner's Signal profile · Not right? Tell us
How we know: a partner's Signal profile · Not right? Tell us
How we know: funding news · privateequitywire.co.uk · Not right? Tell us
Funding
SEC filings, press & company announcements$30M disclosed across 1 round · 2022
- $30MSeries BJun 2022 · 4 sources
4BIO Capital (lead), DCI Partners (lead), Fast Track Initiative (lead)
Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
In the news
Frequently asked questions
- What does LUCA Science do?
- LUCA Science develops mitochondrial therapies that supply functional, storable mitochondria to damaged or dysfunctional cells and tissues to restore cellular energy production, targeting conditions such as ischemia-reperfusion injuries including cerebral and myocardial infarction. The company works in the biopharmaceutical field, building a platform based on its proprietary iMIT mitochondria technology.
- Who are LUCA Science's investors?
- LUCA Science's investors include Asahi Kasei Corporate Venture Capital, Fast Track Initiative, Remiges Ventures, Inc., 4BIO Capital, Astellas Venture Management LLC, Axil Capital, DCI Partners Co. Ltd..
- How much funding has LUCA Science raised?
- LUCA Science has disclosed $30M raised across 1 round.